Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care

Diabetic Medicine - Tập 24 Số 4 - Trang 350-358 - 2007
Michael N. Cook1, Cynthia J. Girman2, Peter Stein2, Charles M. Alexander3
1Department of Epidemiology, Merck Research Laboratories, West Point, PA 19486-0004, USA.
2Departments of Epidemiology and Clinical Research–Metabolism, Merck Research Laboratories and
3Outcomes Research & Management, Merck & Co., Inc., West Point, PA, USA.

Tóm tắt

AbstractAims  To describe initial achievement of glycaemic targets and subsequent hyperglycaemia in patients with Type 2 diabetes managed with oral agent monotherapy in UK primary care from 1998 to 2004.Methods  Electronic medical records of patients initiating metformin (n = 3362) or a sulphonylurea agent (n = 3070) in 290 UK primary care practices were retrieved from the General Practice Research Database (GPRD). Patients included had an HbA1c recorded 0–90 days before and 90–365 days after initiating monotherapy. The probability of achieving glycaemic thresholds in the first year, and for those achieving such targets, the probability of inadequate glycaemic control (HbA1c > 6.5%, > 7.0%, > 7.5%) over time is described.Results  Low baseline HbA1c and drug initiation within 3 months of diabetes diagnosis were the strongest predictors of initial achievement of glycaemic targets. The proportion of patients with diabetes duration ≥ 4 months who achieved HbA1c < 7% in the first year ranged from 24% to 88% for highest to lowest baseline HbA1c category in sulphonylurea initiators and from 19% to 86% in metformin initiators, with slightly higher proportions for newly diagnosed patients. Kaplan–Meier analyses suggested that 55% and 70% of patients who initially achieved glycaemic targets had HbA1c measurements above these targets at 2 and 3 years.Conclusions  Many patients fail to achieve glycaemic goals with initial monotherapy and, of those who achieve current goals, few consistently maintain these targets over 3 years. Research is needed to evaluate whether more aggressive treatment or alternative treatments can improve the long‐term maintenance of glycaemic control in patients with Type 2 diabetes.

Từ khóa


Tài liệu tham khảo

10.1046/j.1464-5491.2003.00972.x

10.2337/diacare.27.5.1047

10.1111/j.1600-051X.1988.tb01003.x

Department of Health., 2003, Diabetes Information Strategy.

British Medical Association., 2003, The New GMS Contract: Investing in General Practice.

National Institute for Clinical Excellence (NICE)., 2002, Inherited Clinical Guideline G. Management of Type 2 Diabetes: Management of Blood Glucose.

UKPDS Group., 1995, UK Prospective Diabetes Study 16: Overview of six years’ therapy of type 2 diabetes—a progressive disease, Diabetes, 44, 1249, 10.2337/diab.44.11.1249

10.1001/jama.281.21.2005

10.2165/00002018-200427120-00004

Office for National Statistics., 2000, Key Health Statistics from General Practice 1998.

Davis S, 2003, Auditing the quality of data in the General Practice Research Database (Abstract), Pharmacoepidemiol Drug Safety, 12, S61

10.7326/0003-4819-141-6-200409210-00007

10.7326/0003-4819-141-6-200409210-00006

10.2337/diacare.28.suppl_1.S4

IDF Clinical Guidelines Task Force., 2005, Global Guideline for Type 2 Diabetes.

Diabetes Medical Guideline Task Force., 2002, The American association of clinical endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self‐management—2002 update, Endocrine Pract, 8, 41

10.1016/S0140-6736(98)07037-8

10.1002/pds.1089

10.1056/NEJM198911023211805

10.1056/NEJMoa012512

10.1136/bmj.310.6972.83

10.1093/qjmed/hcg040

10.2337/diacare.28.5.995

10.2337/diacare.27.7.1535

10.2337/diacare.29.03.06.dc05-1937

Thông tin
Thông tin xuất bản

Diabetic Medicine

Tập 24 Số 4

350-358

Thông tin tác giả